Atossa Therapeutics, Inc. (ATOS)

1.4200 -0.0300 (-2.07%) At close: 04:00PM EDT

Atossa Therapeutics, Inc.

107 Spring Street
Seattle, WA 98104
United States
206 588 0256
https://www.atossatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 12

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Steven C. Quay FCAP, M.D., Ph.D.	Chairman, CEO & President	1.21M	N/A	1951
Ms. Heather Rees CPA	Chief Financial Officer & Principal Accounting Officer	520.64k	N/A	1973
Ms. Delly Behen P.H.R.	Senior Vice President of Administration & HR	N/A	N/A	N/A
Mr. Eric Van Zanten	Vice President of Investor & Public Relations	N/A	N/A	N/A
Dr. Richard Graydon M.D., Ph.D.	Interim Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Corporate Governance

Atossa Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.